2026-08-29T14:15:17Zhttps://repisalud.isciii.es/rest/oai/request
oai:repisalud.isciii.es:20.500.12105/180582024-11-28T14:47:13Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16927
Repisalud author Decara, Juan author Rivera, Patricia author López-Gambero, Antonio Jesús author Serrano, Antonia author Pavón, Francisco-Javier author Baixeras, Elena author Rodríguez de Fonseca, Fernando author Suárez, Juan authoraffiliation [Decara,J; López-Gambero,AJ; Serrano,A; Pavón, Francisco-Javier; Rodríguez de Fonseca,F; Suárez,J] UGC Salud Mental, Instituto de Investigación Biomédica de Málaga (IBIMA), Hospital Regional Universitario de Málaga, Universidad de Málaga, Málaga, Spain. [Rivera,P] Departamento de Endocrinología, Fundación Investigación Biomédica del Hospital Infantil Universitario Niño Jesús, Madrid, Spain. [Pavón,FJ] Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV) and UGC del Corazón, Instituto de Investigación Biomédica de Málaga (IBIMA), Hospital Universitario Virgen de la Victoria, Universidad de Málaga, Málaga, Spain. [Baixeras,E] Departamento de Bioquímica y Biología Molecular, Facultad de Medicina, Universidad de Málaga, IBIMA, Málaga, Spain. 2024-02-12T19:46:24Z 2024-02-12T19:46:24Z 2020-05-27 10.3389/fphar.2020.00730 1663-9812 Frontiers in Pharmacology http://hdl.handle.net/10668/3629 32536865 http://hdl.handle.net/20.500.12105/18058 The peroxisome proliferator-activated receptors (PPARs) are a group of nuclear receptor proteins that promote ligand-dependent transcription of target genes that regulate energy production, lipid metabolism, and inflammation. The PPAR superfamily comprises three subtypes, PPARα, PPARγ, and PPARβ/δ, with differential tissue distributions. In addition to their different roles in the regulation of energy balance and carbohydrate and lipid metabolism, an emerging function of PPARs includes normal homeostasis of intestinal tissue. PPARα activation represses NF-κB signaling, which decreases the inflammatory cytokine production by different cell types, while PPARγ ligands can inhibit activation of macrophages and the production of inflammatory cytokines, such as tumor necrosis factor-alpha (TNF-α), interleukin (IL)-6, and Il-1β. In this regard, the anti-inflammatory responses induced by PPAR activation might restore physiopathological imbalances associated with inflammatory bowel diseases (IBD). Thus, PPARs and their ligands have important therapeutic potential. This review briefly discusses the roles of PPARs in the physiopathology and therapies of the most important IBDs, ulcerative colitis (UC), and Crohn's disease (CD), as well some new experimental compounds with PPAR activity as promising drugs for IBD treatment. eng PPARa PPARg PPARb/d Inflammatory bowel diseases Ulcerative colitis Crohn's disease Receptores activados del proliferador del peroxisoma Enfermedades inflamatorias del intestino Colitis ulcerosa Enfermedad de Crohn Peroxisome Proliferator-Activated Receptors: Experimental Targeting for the Treatment of Inflammatory Bowel Diseases review article